A novel recombinant human parainfluenza virus type 1 (rHPIV1), rHPIV1-C+P, in which the overlapping open reading frames of the C and P genes were separated in order to introduce mutations into the C gene without affecting P, was generated. Infectious rHPIV1-C+P was readily recovered and replicated as efficiently as HPIV1 wild type (wt) in vitro and in African green monkeys (AGMs). rHPIV1-C+P expressed increased levels of C protein and, surprisingly, activated the type I IFN and apoptosis responses more strongly than HPIV1 wt. rHPIV1-C+P provided a useful backbone for recovering an attenuated P/C gene mutation (Delta 84-85), which was previously unrecoverable, likely due to detrimental effects of the deletion on the P protein. rHPIV1-C(Delta 84-85)+P and an additional mutant, rHPIV1-C(Delta 169-170)+P, were found to replicate to similar titers in vitro and to activate the type I IFN and apoptosis responses to a similar degree as rHPIV1-C+P. rHPIV1-C(Delta 84-85)+P was found to be highly attenuated in AGMs, and all viruses were immunogenic and effective in protecting AGMs against challenge with HPIV1 wt. rHPIV1-C(Delta 84-85)+P will be investigated as a potential live-attenuated vaccine candidate for HPIV1.
A novel recombinant human parainfluenza virus type 1 (rpan class="Species">HPIV1), rHPIV1-C+P, in which the overlapping open reading frames of the C and P genes were separated in order to introduce mutations into the C gene without affecting P, was generated. Infectious rHPIV1-C+P was readily recovered and replicated as efficiently as HPIV1 wild type (wt) in vitro and in African green monkeys (AGMs). rHPIV1-C+P expressed increased levels of C protein and, surprisingly, activated the type I IFN and apoptosis responses more strongly than HPIV1 wt. rHPIV1-C+P provided a useful backbone for recovering an attenuated P/C gene mutation (Delta 84-85), which was previously unrecoverable, likely due to detrimental effects of the deletion on the P protein. rHPIV1-C(Delta 84-85)+P and an additional mutant, rHPIV1-C(Delta 169-170)+P, were found to replicate to similar titers in vitro and to activate the type I IFN and apoptosis responses to a similar degree as rHPIV1-C+P. rHPIV1-C(Delta 84-85)+P was found to be highly attenuated in AGMs, and all viruses were immunogenic and effective in protecting AGMs against challenge with HPIV1 wt. rHPIV1-C(Delta 84-85)+P will be investigated as a potential live-attenuated vaccine candidate for HPIV1.
Authors: Josephine M McAuliffe; Sonja R Surman; Jason T Newman; Jeffrey M Riggs; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos Journal: J Virol Date: 2004-02 Impact factor: 5.103
Authors: Ruth A Karron; Robert B Belshe; Peter F Wright; Bhagvanji Thumar; Barbars Burns; Frances Newman; Joan C Cannon; Juliette Thompson; Theodore Tsai; Maribel Paschalis; Shin-Lu Wu; Yvonne Mitcho; Jill Hackell; Brian R Murphy; Joanna M Tatem Journal: Pediatr Infect Dis J Date: 2003-05 Impact factor: 2.129
Authors: Marika K Iwane; Kathryn M Edwards; Peter G Szilagyi; Frances J Walker; Marie R Griffin; Geoffrey A Weinberg; Charmaine Coulen; Katherine A Poehling; Laura P Shone; Sharon Balter; Caroline B Hall; Dean D Erdman; Karen Wooten; Benjamin Schwartz Journal: Pediatrics Date: 2004-06 Impact factor: 7.124
Authors: Emmalene J Bartlett; Ann-Marie Cruz; Janice Esker; Adam Castaño; Henrick Schomacker; Sonja R Surman; Margaret Hennessey; Jim Boonyaratanakornkit; Raymond J Pickles; Peter L Collins; Brian R Murphy; Alexander C Schmidt Journal: J Virol Date: 2008-07-09 Impact factor: 5.103
Authors: Judith A Smith; Matthew J Turner; Monica L DeLay; Erin I Klenk; Dawn P Sowders; Robert A Colbert Journal: Eur J Immunol Date: 2008-05 Impact factor: 5.532
Authors: Sheila M Nolan; Mario H Skiadopoulos; Konrad Bradley; Olivia S Kim; Stacia Bier; Emerito Amaro-Carambot; Sonja R Surman; Stephanie Davis; Marisa St Claire; Randy Elkins; Peter L Collins; Brian R Murphy; Anne Schaap-Nutt Journal: Vaccine Date: 2007-07-03 Impact factor: 3.641
Authors: Jason T Newman; Jeffrey M Riggs; Sonja R Surman; Josephine M McAuliffe; Teresa A Mulaikal; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos Journal: J Virol Date: 2004-02 Impact factor: 5.103
Authors: Guruprasad R Medigeshi; Alissa M Lancaster; Alec J Hirsch; Thomas Briese; W Ian Lipkin; Victor Defilippis; Klaus Früh; Peter W Mason; Janko Nikolich-Zugich; Jay A Nelson Journal: J Virol Date: 2007-08-08 Impact factor: 5.103
Authors: David F Stojdl; Brian D Lichty; Benjamin R tenOever; Jennifer M Paterson; Anthony T Power; Shane Knowles; Ricardo Marius; Jennifer Reynard; Laurent Poliquin; Harold Atkins; Earl G Brown; Russell K Durbin; Joan E Durbin; John Hiscott; John C Bell Journal: Cancer Cell Date: 2003-10 Impact factor: 31.743
Authors: Emmalene J Bartlett; Adam Castaño; Sonja R Surman; Peter L Collins; Mario H Skiadopoulos; Brian R Murphy Journal: Virol J Date: 2007-07-02 Impact factor: 4.099
Authors: Alexander C Schmidt; Anne Schaap-Nutt; Emmalene J Bartlett; Henrick Schomacker; Jim Boonyaratanakornkit; Ruth A Karron; Peter L Collins Journal: Expert Rev Respir Med Date: 2011-08 Impact factor: 3.772
Authors: Anne Schaap-Nutt; Rachael Liesman; Emmalene J Bartlett; Margaret A Scull; Peter L Collins; Raymond J Pickles; Alexander C Schmidt Journal: Virology Date: 2012-09-07 Impact factor: 3.616
Authors: Qian Mao; Shengming Ma; Philip Luke Schrickel; Pengwei Zhao; Jingya Wang; Yuhua Zhang; Shuangyu Li; Chengbao Wang Journal: Front Vet Sci Date: 2022-08-02